SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-038620
Filing Date
2023-10-30
Accepted
2023-10-30 09:00:10
Documents
12
Period of Report
2023-10-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48462
  Complete submission text file 0001493152-23-038620.txt   217288

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE otlc-20231024.xsd EX-101.SCH 3018
3 XBRL LABEL FILE otlc-20231024_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE otlc-20231024_pre.xml EX-101.PRE 22361
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3037
Mailing Address 29397 AGOURA RD. #107 AGUORA HILLS CA 91301
Business Address 29397 AGOURA RD. #107 AGUORA HILLS CA 91301 650-635-7000
Oncotelic Therapeutics, Inc. (Filer) CIK: 0000908259 (see all company filings)

IRS No.: 133679168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21990 | Film No.: 231357679
SIC: 2834 Pharmaceutical Preparations